Measles–Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and considerations

Zehrung, Darin, Innis, Bruce L., Suwantika, Auliya A., Ameri, Mahmoud, Biellik, Robin, Birchall, James C. ORCID: https://orcid.org/0000-0001-8521-6924, Cravioto, Alejandro, Jarrahian, Courtney, Fairlie, Lee, Goodson, James L., Kochhar, Sonali, Kretsinger, Katrina, Morgan, Christopher, Mvundura, Mercy, Rathi, Niraj, Clarke, Edward, Mistilis, Jessica Joyce, Uwamwezi, Marie-Chantal, Giersing, Birgitte and Hasso-Agopsowicz, Mateusz 2024. Measles–Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and considerations. Vaccines 12 (11) 10.3390/vaccines12111258

PDF - Published Version Download (1MB)

Abstract

Background: The Measles–Rubella Microarray Patch (MR-MAP) is an important technology that is expected to reduce coverage and equity gaps for measles-containing vaccines (MCVs), reach zero-dose children, and contribute to elimination of measles and rubella. MR-MAPs are anticipated to be easier to deploy programmatically and could be delivered by lesser-trained health workers, thereby increasing immunization coverage. The most advanced MR-MAP has reached clinical proof-of-concept through a Phase I/II trial in the target population of infants and young children. The World Health Organization (WHO) and partners have developed the Phase III clinical trial framework for MR-MAPs presented in this article. Objectives and Methods: The purpose of such framework is to inform the considerations, design and approach for the pivotal clinical trial design, while considering the anticipated data requirements to inform regulatory approval, WHO prequalification, and policy decision. Results: The proposed Phase III trial would compare the immunogenicity and safety of an MR-MAP with MR vaccine delivered subcutaneously in 9- to 10-month-old infants. An analysis of non-inferiority (NI) of immunogenicity would occur six weeks after the first dose. Should regulatory agencies or policy makers require, a proportion of infants could receive a second dose of either the same or alternate MR vaccine presentation six months after the first dose, with those children returning six weeks after the second dose for a descriptive assessment of immunogenicity, and then followed up six months after the second dose for evaluation of safety and immunogenicity. It is anticipated that this proposed pivotal Phase III trial framework would generate the required clinical data for regulatory licensure and WHO prequalification (PQ) of MR-MAPs. However, the trial design would need to be reviewed and confirmed by a national regulatory authority (NRA) that will assess the product for regulatory licensure and the WHO PQ team. Additional research will likely be required to generate data on concomitant vaccine delivery, the safety and immunogenicity of MR-MAPs in other age groups such as children 1–5 years and infants younger than 9 months of age, and the impact of MR-MAPs on coverage and equity. Such studies could be conducted during or after clinical MR-MAP development.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Pharmacy
Additional Information:	License information from Publisher: LICENSE 1: URL: https://creativecommons.org/licenses/by/4.0/, Start Date: 2024-11-06
Publisher:	MDPI
ISSN:	2076-393X
Date of First Compliant Deposit:	15 November 2024
Date of Acceptance:	25 October 2024
Last Modified:	09 Dec 2024 16:58
URI:	https://orca.cardiff.ac.uk/id/eprint/174026

Actions (repository staff only)

Edit Item